Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

abstract Objective: The aim was to formulate practice guidelines for the diagnosis and
treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Prolactinomas account for approximately 40% of all pituitary adenomas and are an
important cause of hypogonadism and infertility. The ultimate goal of therapy for …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Pituitary adenomas are common intracranial tumors that are mainly considered as benign.
Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Context: Although pituitary tumors are common, pituitary carcinoma is very rare and is only
diagnosed when pituitary tumor noncontiguous with the sellar region is demonstrated …

Context: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with
temozolomide have been reported. Increased expression of O 6-methylguanine-DNA …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …